Abstract
Angiogenesis is an important event for organ development and regeneration via supply of nutrition and oxygen. Appropriate cellular responses, such as endothelial cell (EC) growth, are involved in the angiogenic actions, especially under hypoxic conditions. Hepatocyte growth factor (HGF) is now an organotrophic factor that is essential for organ development and tissue regeneration. In addition, HGF is the most potent angiogenic growth factor in culture of ECs, with mitogenic, and morphogenic functions via activation of c-Met/HGF-receptor. In hypoxic diseases, such as coronary arterial disease (CAD), up-regulation of HGF production is transient, followed by the HGF-deficient conditions, along with the lowered angiogenesis and enhanced hypoxia. Enhancement of angiogenesis by exogenous HGF leads to the improvement in heart dysfunction. Such angio-therapeutic effects of HGF are also seen in various hypoxic diseases, such as skin ulcer and lung emphysema. In tumor tissues, angiogenesis is required for cancer growth and metastasis. Indeed, an HGF-antagonist, NK4, potently inhibits tumor angiogenesis and metastasis in mouse models of malignant tumors. These provide a rationale why HGF is useful for the improvement in CAD and other ischemic diseases and NK4 for the suppression of tumor malignancy. Importantly, appropriate HGF-c-Met signal is required for sustaining homeostasis in normal tissue. Herein, we provide a concept that amount of HGF may determine the predisposition to ischemic disease, healthy conditions, or neoplastic disease, all of which depend on the degree of c-Met activation, and in part, concomitant angiogenic activity.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ando J, Kamiya A (1993) Blood flow and vascular endothelial cell function. Front Med Biol Eng 5:245–264
Staudacher DL, Preis M, Lewis BS et al (2006) Cellular and molecular therapeutic modalities for arterial obstructive syndromes. Pharmacol Ther 109:263–273
Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31
Nakamura T, Nawa K, Ichihara A (1984) Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 122:1450–1459
Nakamura T, Nawa K, Ichihara A et al (1987) Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett 224:311–316
Nakamura T, Nishizawa T, Hagiya M et al (1989) Molecular cloning and expression of human hepatocyte growth factor. Nature 342:440–443
Tashiro K, Hagiya M, Nishizawa T et al (1990) Deduced primary structure of rat hepatocyte growth factor and expression of the mRNA in rat tissues. Proc Natl Acad Sci USA 87:3200–3204
Dean M, Park M, Le Beau MM et al (1985) The human met oncogene is related to the tyrosine kinase oncogenes. Nature 318:385–388
Bottaro DP, Rubin JS, Faletto DL et al (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802–804
Higuchi O, Mizuno K, Vande Woude GF, Nakamura T (1992) Expression of c-met proto-oncogene in COS cells induces the signal transducing high-affinity receptor for hepatocyte growth factor. FEBS Lett 301:282–286
Schaeper U, Gehring NH, Fuchs KP et al (2000) Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J Cell Biol 149:1419–1432
Nakamura T, Mizuno S (2010) The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci 86:588–610
Ishiki Y, Ohnishi H, Muto Y et al (1992) Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo. Hepatology 16:1227–1235
Honda S, Kagoshima M, Wanaka A et al (1995) Localization and functional coupling of HGF and c-Met/HGF receptor in rat brain: implication as neurotrophic factor. Brain Res Mol Brain Res 32:197–210
Nakamura T, Mizuno S, Matsumoto K et al (2000) Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 106:1511–1519
Bussolino F, Di Renzo MF, Ziche M et al (1992) Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119:629–641
Nakamura Y, Morishita R, Nakamura S et al (1996) A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension 28:409–413
Morishita R, Aoki M, Hashiya N et al (2004) Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr Gene Ther 4:199–206
Matsumoto K, Nakamura T (2003) NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 94:321–327
Montesano R, Matsumoto K, Nakamura T, Orci L (1991) Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67:901–908
Nakamura Y, Morishita R, Higaki J et al (1995) Expression of local hepatocyte growth factor system in vascular tissues. Biochem Biophys Res Commun 215:483–488
Machide M, Hashigasako A, Matsumoto K, Nakamura T (2006) Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase. J Biol Chem 281:8765–8772
Ding S, Merkulova-Rainon T, Han ZC et al (2003) HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood 101:4816–4822
Scarpino S, Cancellario d’Alena F, Di Napoli A et al (2004) Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol 202:352–358
Morishita R, Nakamura S, Hayashi S et al (1999) Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 33:1379–1384
Hayashi S, Morishita R, Nakamura S et al (1999) Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. Circulation 100:II301–II308
Nakagami H, Morishita R, Yamamoto K et al (2001) Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension 37:581–586
Van Belle E, Witzenbichler B, Chen D et al (1998) Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 97:381–390
Liu Y, Wilkinson FL, Kirton JP et al (2007) Hepatocyte growth factor and c-Met expression in pericytes: implications for atherosclerotic plaque development. J Pathol 212:12–19
Martin TA, Mansel R, Jiang WG (2001) Hepatocyte growth factor modulates vascular endothelial-cadherin expression in human endothelial cells. Clin Cancer Res 7:734–737
Grant DS, Kleinman HK, Goldberg ID et al (1993) Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 90:1937–1941
Wang H, Keiser JA (2000) Hepatocyte growth factor enhances MMP activity in human endothelial cells. Biochem Biophys Res Commun 272:900–905
Purdie KJ, Whitley GS, Johnstone AP, Cartwright JE (2002) Hepatocyte growth factor- induced endothelial cell motility is mediated by the upregulation of inducible nitric oxide synthase expression. Cardiovasc Res 54:659–668
Aoyagi M, Yamamoto S, Azuma H et al (1999) Localization and effects of hepatocyte growth factor on smooth muscle cells during neointimal formation after balloon denudation. Histochem Cell Biol 111:419–428
Taher TE, Derksen PW, de Boer OJ et al (2002) Hepatocyte growth factor triggers signaling cascades mediating vascular smooth muscle cell migration. Biochem Biophys Res Commun 298:80–86
Kobayashi H, DeBusk LM, Babichev YO et al (2006) Hepatocyte growth factor mediates angiopoietin-induced smooth muscle cell recruitment. Blood 108:1260–1266
Zhao J, Wang W, Ha CH et al (2011) Endothelial Grb2-associated binder 1 is crucial for postnatal angiogenesis. Arterioscler Thromb Vasc Biol 31:1016–1023
Kanda S, Kanetake H, Miyata Y (2006) HGF-induced capillary morphogenesis of endothelial cells is regulated by Src. Biochem Biophys Res Commun 344:617–622
Somlyo AV, Phelps C, Dipierro C et al (2003) Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. FASEB J 17:223–234
Morishita R, Nakamura S, Nakamura Y et al (1997) Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes. Diabetes 46:138–142
Liu F, Schaphorst KL, Verin AD et al (2002) Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3beta. FASEB J 16:950–962
Birukova AA, Alekseeva E, Mikaelyan A, Birukov KG (2007) HGF attenuates thrombin-induced endothelial permeability by Tiam1-mediated activation of the Rac pathway and by Tiam1/Rac-dependent inhibition of the Rho pathway. FASEB J 21:2776–2786
Singleton PA, Salgia R, Moreno-Vinasco L et al (2007) CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem 282:30643–30657
Birukova AA, Cokic I, Moldobaeva N, Birukov KG (2009) Paxillin is involved in the differential regulation of endothelial barrier by HGF and VEGF. Am J Respir Cell Mol Biol 40:99–107
Kim I, Moon SO, Kim SH et al (2001) Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 276:7614–7620
Kaga T, Kawano H, Sakaguchi M et al (2012) Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor. Vascul Pharmacol 57:3–9
Mizuno S, Nakamura T (2005) Prevention of neutrophil extravasation by hepatocyte growth factor leads to attenuations of tubular apoptosis and renal dysfunction in mouse ischemic kidneys. Am J Pathol 166:1895–1905
Min JK, Lee YM, Kim JH et al (2005) Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. Circ Res 96:300–307
Kamimoto M, Mizuno S, Matsumoto K, Nakamura T (2009) Hepatocyte growth factor prevents multiple organ injuries in endotoxemic mice through a heme oxygenase-1-dependent mechanism. Biochem Biophys Res Commun 380:333–337
Hayashi S, Morishita R, Higaki J et al (1996) Autocrine-paracrine effects of overexpression of hepatocyte growth factor gene on growth of endothelial cells. Biochem Biophys Res Commun 220:539–545
Kuba K, Matsumoto K, Date K et al (2000) HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 60:6737–6743
Rush S, Khan G, Bamisaiye A et al (2007) c-jun amino-terminal kinase and mitogen activated protein kinase 1/2 mediate hepatocyte growth factor-induced migration of brain endothelial cells. Exp Cell Res 313:121–132
Soeki T, Tamura Y, Shinohara H et al (2000) Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease. Heart Vessels 15:105–111
Zhu Y, Hojo Y, Ikeda U, Shimada K (2000) Production of hepatocyte growth factor during acute myocardial infarction. Heart 83:450–455
Ono K, Matsumori A, Shioi T et al (1997) Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 95:2552–2558
Aoki M, Morishita R, Taniyama Y et al (2000) Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther 7:417–427
Nakamura T, Matsumoto K, Mizuno S et al (2005) Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts. Am J Physiol Heart Circ Physiol 288:H2131–H2139
Li Y, Takemura G, Kosai K et al (2003) Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation 107:2499–2506
Jayasankar V, Woo YJ, Pirolli TJ et al (2005) Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure. J Card Surg 20:93–101
Yamaguchi T, Sawa Y, Miyamoto Y et al (2005) Therapeutic angiogenesis induced by injecting hepatocyte growth factor in ischemic canine hearts. Surg Today 35:855–860
Taniyama Y, Morishita R, Aoki M et al (2002) Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension 40:47–53
Yasuda S, Noguchi T, Gohda M et al (2000) Single low-dose administration of human recombinant hepatocyte growth factor attenuates intimal hyperplasia in a balloon-injured rabbit iliac artery model. Circulation 101:2546–2549
Hayashi K, Nakamura S, Morishita R et al (2000) In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther 7:1664–1671
Bessho K, Mizuno S, Matsumoto K, Nakamura T (2003) Counteractive effects of HGF on PDGF-induced mesangial cell proliferation in a rat model of glomerulonephritis. Am J Physiol Renal Physiol 284:F1171–F1180
Sanada F, Taniyama Y, Iekushi K et al (2009) Negative action of hepatocyte growth factor/c-Met system on angiotensin II signaling via ligand-dependent epithelial growth factor receptor degradation mechanism in vascular smooth muscle cells. Circ Res 105:667–675
Mizuno S, Matsumoto K, Li MY, Nakamura T (2005) HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J 19:580–582
Mizuno S, Nakamura T (2012) Improvement of sepsis by hepatocyte growth factor, an anti-inflammatory regulator: emerging insights and therapeutic potential. Gastroenterol Res Pract 2012:909350
Yoshitomi Y, Kojima S, Umemoto T et al (1999) Serum hepatocyte growth factor in patients with peripheral arterial occlusive disease. J Clin Endocrinol Metab 84:2425–2428
Yoshida S, Matsumoto K, Tomioka D et al (2004) Recombinant hepatocyte growth factor accelerates cutaneous wound healing in a diabetic mouse model. Growth Factors 22:111–119
Taniyama Y, Morishita R, Hiraoka K et al (2001) Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 104:2344–2350
Vajanto I, Rissanen TT, Rutanen J et al (2002) Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J Gene Med 4:371–380
Tsuzuki N, Miyazawa T, Matsumoto K et al (2001) Hepatocyte growth factor reduces the infarct volume after transient focal cerebral ischemia in rats. Neurol Res 23:417–424
Yoshimura S, Morishita R, Hayashi K et al (2002) Gene transfer of hepatocyte growth factor to subarachnoid space in cerebral hypoperfusion model. Hypertension 39:1028–1034
Shimamura M, Sato N, Oshima K et al (2004) Novel therapeutic strategy to treat brain ischemia: overexpression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat model. Circulation 109:424–431
Date I, Takagi N, Takagi K et al (2004) Hepatocyte growth factor attenuates cerebral ischemia-induced learning dysfunction. Biochem Biophys Res Commun 319:1152–1158
Miyazawa T, Matsumoto K, Ohmichi H et al (1998) Protection of hippocampal neurons from ischemia-induced delayed neuronal death by hepatocyte growth factor: a novel neurotrophic factor. J Cereb Blood Flow Metab 18:345–348
Takeuchi D, Sato N, Shimamura M et al (2008) Alleviation of Abeta-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model. Gene Ther 15:561–571
Ono M, Sawa Y, Matsumoto K et al (2002) In vivo gene transfection with hepatocyte growth factor via the pulmonary artery induces angiogenesis in the rat lung. Circulation 106:I264–I269
Shigemura N, Sawa Y, Mizuno S et al (2005) Amelioration of pulmonary emphysema by in vivo gene transfection with hepatocyte growth factor in rats. Circulation 111:1407–1414
Ishizawa K, Kubo H, Yamada M et al (2004) Hepatocyte growth factor induces angiogenesis in injured lungs through mobilizing endothelial progenitor cells. Biochem Biophys Res Commun 324:276–280
Ono M, Sawa Y, Mizuno S et al (2004) Hepatocyte growth factor suppresses vascular medial hyperplasia and matrix accumulation in advanced pulmonary hypertension of rats. Circulation 110:2896–2902
Mizuno S, Nakamura T (2011) Hydrodynamics, Chap 6. In: Schulz HA, Anfrade AL, Lobosco RJ (eds) Endocrine delivery system of NK4, an HGF antagonistic and anti-angiogenic regulator, for controlling tumor growth and metastasis, 1st edn. InTECH publisher, Rijeka, Croatia, pp 119–142
Kajiya K, Hirakawa S, Ma B et al (2005) Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 24:2885–2895
Zhang YW, Su Y, Volpert OV, Vande Woude GF (2003) Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 100:12718–12723
Lee WJ, Chen WK, Wang CJ et al (2008) Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol 226:178–191
Tsarfaty G, Stein GY, Moshitch-Moshkovitz S et al (2006) HGF/SF increases tumor blood volume: a novel tool for the in vivo functional molecular imaging of Met. Neoplasia 8:344–352
Jiang WG, Martin TA, Matsumoto K et al (1999) Hepatocyte growth factor/scatter factor decreases the expression of occludin and transendothelial resistance (TER) and increases paracellular permeability in human vascular endothelial cells. J Cell Physiol 181:319–329
Date K, Matsumoto K, Shimura H et al (1997) HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 420:1–6
Matsumoto K, Kataoka H, Date K, Nakamura T (1998) Cooperative interaction between alpha- and beta-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses. J Biol Chem 273:22913–22920
Laterra J, Nam M, Rosen E et al (1997) Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab Invest 76:565–577
Jiang WG, Hiscox SE, Parr C et al (1999) Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clin Cancer Res 5:3695–3703
Matsumoto K, Matsumoto K, Nakamura T, Kramer RH (1994) Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J Biol Chem 269:31807–31813
Nakamura T, Matsumoto K, Kiritoshi A et al (1997) Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res 57:3305–3313
Date K, Matsumoto K, Kuba K et al (1998) Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 17:3045–3054
Tomioka D, Maehara N, Kuba K et al (2001) Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 61:7518–7524
Wen J, Matsumoto K, Taniura N et al (2004) Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther 11:419–430
Suzuki Y, Sakai K, Ueki J et al (2010) Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma. Int J Cancer 127:1948–1957
Matsumoto K, Nakamura T (2005) Mechanisms and significance of bifunctional NK4 in cancer treatment. Biochem Biophys Res Commun 333:316–327
Kikuchi T, Maemondo M, Narumi K et al (2002) Tumor suppression induced by intratumor administration of adenovirus vector expressing NK4, a 4-kringle antagonist of hepatocyte growth factor, and naive dendritic cells. Blood 100:3950–3959
Hirao S, Yamada Y, Koyama F et al (2002) Tumor suppression effect using NK4, a molecule acting as an antagonist of HGF, on human gastric carcinomas. Cancer Gene Ther 9:700–707
Namiki Y, Namiki T, Yoshida H et al (2006) Preclinical study of a “tailor-made” combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer. Int J Cancer 118:1545–1555
Brockmann MA, Papadimitriou A, Brandt M et al (2003) Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res 9:4578–4585
Heideman DA, Overmeer RM, van Beusechem VW et al (2005) Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy. Cancer Gene Ther 12:954–962
Du W, Hattori Y, Yamada T et al (2007) NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood 109:3042–3049
Saga Y, Mizukami H, Suzuki M et al (2001) Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival. Gene Ther 8:1450–1455
Davies G, Mason MD, Martin TA et al (2003) The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo. Int J Cancer 106:348–354
Sakai K, Nakamura T, Matsumoto K, Nakamura T (2009) Angioinhibitory action of NK4 involves impaired extracellular assembly of fibronectin mediated by perlecan-NK4 association. J Biol Chem 284:22491–22499
Siltanen A, Kitabayashi K, Lakkisto P et al (2011) hHGF overexpression in myoblast sheets enhances their angiogenic potential in rat chronicheart failure. PLoS One 6:e19161
Buchstein N, Hoffmann D, Smola H et al (2009) Alternative proteolytic processing of hepatocyte growth factor during wound repair. Am J Pathol 174:2116–2128
Nayeri F, Strömberg T, Larsson M et al (2002) Hepatocyte growth factor may accelerate healing in chronic leg ulcers: a pilot study. J Dermatolog Treat 13:81–86
Shigematsu H, Yasuda K, Iwai T et al (2010) Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 17:1152–1161
Makino H, Aoki M, Hashiya N et al (2012) Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arterioscler Thromb Vasc Biol 32:2503–2509
Yuan B, Zhao Z, Zhang YR et al (2008) Short-term safety and curative effect of recombinant adenovirus carrying hepatocyte growth factor gene on ischemic cardiac disease. In Vivo 22:629–632
Acknowledgements
This work was supported by grants from the Ministry of Education, Science, Technology, Sports and Culture of Japan (No. 23590458 to S.M. and No. 21390079 and Global COE program to T.N.). We also thank Mrs. Yoshiko Yoneda for secretarial assistance.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ohnishi, H., Mizuno, S., Oka, K., Nakamura, T. (2013). Physiological Roles and Therapeutic Implications of Hepatocyte Growth Factor for Angiogenesis. In: Mehta, J., Dhalla, N. (eds) Biochemical Basis and Therapeutic Implications of Angiogenesis. Advances in Biochemistry in Health and Disease, vol 6. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5857-9_22
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5857-9_22
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5856-2
Online ISBN: 978-1-4614-5857-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)